We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

32 hedge funds and large institutions have $4.03M invested in CASI Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

7% more funds holding

Funds holding: 30 → 32 (+2)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

30% less capital invested

Capital invested by funds: $5.76M → $4.03M (-$1.73M)

Holders
32
Holders Change
+2
Holders Change %
+6.67%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$74.7K
2
WJA
Williams Jones & Associates
New York
+$25.2K
3
Renaissance Technologies
Renaissance Technologies
New York
+$22.4K
4
Citadel Advisors
Citadel Advisors
Florida
+$17.4K
5
MC
Moors & Cabot
Massachusetts
+$5.17K

Top Sellers

Rank Fund Capital Flow
1
WSCM
Wellington Shields Capital Management
New York
-$439K
2
MHP
Manatuck Hill Partners
Connecticut
-$27K
3
WSC
Wellington Shields & Co
New York
-$21.5K
4
EEG
E.E. Geduld
-$15.7K
5
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$1K

CASI Hedge Fund Activity: Q4 2014 in Review

32 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2014, worth a combined $4.03M — down 30% from $5.76M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CASI positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Sabby Management, adding an estimated $74.7K. The largest seller was Wellington Shields Capital Management, cutting an estimated $439K.

  • 32 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2014, up from 30 in Q3 2014.
  • Funds reported $4.03M of CASI Pharmaceuticals stock for Q4 2014, down 30% quarter-over-quarter.
  • 6 funds opened new CASI Pharmaceuticals positions in Q4 2014 and 3 closed out, a net change of +3 holders.
  • The largest CASI Pharmaceuticals buyer in Q4 2014 was Sabby Management, an estimated $74.7K added.
  • The largest CASI Pharmaceuticals seller in Q4 2014 was Wellington Shields Capital Management, an estimated $439K sold.

Based on aggregated 13F filings for Q4 2014.